MediVision Medical Imaging Ltd. ?+(972) 4-989-4884 ?+(972) 4-989-4883

? 26 Sweden St. Haifa, Israel 34980

REGULATED INFORMATION

? noam@medivision.co.il

Communication in accordance with article 15 of the transparency regulations

Haifa, Israel, June 18th, 2013 8:30 - In accordance with Article 15 of the Law of May 2007 regarding the transparency regulations, MediVision Medical Imaging Ltd. (Euronext Brussels symbol: MEDV) proceeds with the publication of the following information (as of August 5th, 2011):

Total amount of Company capital, fully paid up

$1,036,854

Total number of shares with voting rights

36,410,135

Total number of voting rights (denominator)

36,410,135

This information as well as other financial information can also be consulted on the Company's website (www.

medivision.co.il) under - Investor Relations tab.


This Report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and information currently available to the Management of the Company. Such statements reflect the current views of th e Company with respect to future events, the outcome of which is subject to certain risks including but not limited to as listed below and other factors, which may be outside of the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticipated, b elieved, estimated, expected or intended. Such abovementioned risks include but are not limited to:
1. Uncertain market acceptance of Company products - The Company's future growth and profitability will depend, in large part, on the acceptance by the market of the Company's existing and proposed products. This acceptance will be substantially dependent on educating the market as to full capabilities, distinctive characteristics, perceived benefits and efficacy of the
Company's existing and proposed products. In addition, the future success of the Company's products will depend on their acce ptance by customers and on such customers' willingness and
ability to purchase such products. There can be no assurance that the Company's products will receive the necessary market ac ceptance. Failure of the Company's existing and/or proposed
products to gain market acceptance could have a material adverse effect on the Company's business, financial condition and results of operations.

2. New products - The Company, through its Research and Development teams, engages in the development of new technologies and products and in the upgrading and improvement of

existing ones. There is no certainty that development of these technologies and/or products will be completed, successfully, or at all, or i f completed successfully, that a market for them will exist.

distributed by